Letter by Mezzaroma, et al Regarding Article, "NLRP3 inflammasome as a therapeutic target in myocardial infarction"

International Heart Journal

Volumn 55, Issue 4, 2014, Pages 379-

  Mezzaroma, Eleonora ^a   Marchetti, Carlo ^a   Toldo, Stefano ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME;

ACUTE HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; ISCHEMIA; LETTER; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; TISSUE REACTION;

ANIMALS; CARRIER PROTEINS; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; MYOCARDIAL INFARCTION;

EID: 84904107470     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.14-140     Document Type: Letter

References (5)

1. Takahashi M. NLRP3 Inflammasome as a novel player in myocardial infarction. Int Heart J 2014; 55: 101-5. (Review)
2. Van Tassell BW, Toldo S, Mezzaroma E, Abbate A. Targeting interleukin-1 in heart disease. Circulation 2013; 128: 1910-23.
3. O'brien LC, Mezzaroma E, Van Tassell BW, et al. Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure. Mol Med 2014. (in press)
4. Venkatachalam K, Prabhu SD, Reddy VS, Boylston WH, Valente AJ, Chandrasekar B. Neutralization of interleukin-18 ameliorates ischemia/reperfusion-induced myocardial injury. J Biol Chem 2009; 284: 7853-65.
5. Marchetti C, Chojnacki J, Toldo S, et al. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. J Cardiovasc Pharmacol 2014; 63: 316-22.